Literature DB >> 6380870

Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

P Pentel, N Benowitz.   

Abstract

In the drug therapy of cardiac emergencies, it is necessary to rapidly achieve therapeutic drug concentrations and adjust drug dose as the patient's clinical status changes. Cardiac dysfunction is often present and may alter drug pharmacokinetics. Circulatory failure causes sympathetically mediated vasoconstriction in most tissues, with relative sparing of the brain and heart due to autoregulation. Blood flow to vasoconstricted tissues is reduced, and the available cardiac output is redistributed so that the heart and brain receive a greater fraction. Drug distribution to tissues is therefore slowed, and the initial concentration of drug in blood is higher when circulatory failure is present than when it is absent. This higher blood concentration is reflected by higher concentrations of drug in the brain and heart, which are relatively well perfused. Initial doses of many drugs need to be reduced in patients with circulatory failure to prevent cardiac or central nervous system toxicity. Cardiac output is markedly diminished during cardiopulmonary resuscitation (CPR), but blood flow distribution is qualitatively similar to that of circulatory failure with spontaneous circulation. Pneumatic trousers increase lower extremity vascular resistance and may produce a similar redistribution of blood flow. Drug distribution during the use of CPR or pneumatic trousers should be similar to that of circulatory failure with spontaneous circulation, but few data are available to guide drug dosing during the use of these interventions. Animal data suggest that the central volume of distribution of some drugs during CPR may be as small as one-tenth of normal. Drug metabolism in circulatory failure may be impaired by reduced hepatic blood flow resulting in decreased clearance of highly extracted drugs, or by hepatocellular dysfunction resulting in decreased clearance of poorly extracted drugs. Drug excretion may be impaired by reduced renal blood flow resulting in decreased filtration or secretion and increased reabsorption. The maintenance dose of many drugs must therefore be reduced in the presence of circulatory failure. Intravenous drug administration is preferred in patients with circulatory failure. The central intravenous route is often convenient but must be used cautiously when administering potentially cardiotoxic drugs. Intratracheal administration appears to be a promising alternative for some drugs, such as adrenaline (epinephrine). Intracardiac injections are hazardous and offer no demonstrated advantage over other routes.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380870     DOI: 10.2165/00003088-198409040-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  149 in total

1.  Partition of blood flow to the cutaneous and muscular beds of the forearm at rest and during leg exercise in normal subjects and in patients with heart failure.

Authors:  R Zelis; D T Mason; E Braunwald
Journal:  Circ Res       Date:  1969-06       Impact factor: 17.367

2.  Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure.

Authors:  H DeMots; S H Rahimtoola; J H McAnulty; G A Porter
Journal:  Am J Cardiol       Date:  1978-01       Impact factor: 2.778

3.  Administration of heparin causes in vitro release of non-esterified fatty acids in human plasma.

Authors:  K M Giacomini; S E Swezey; J C Giacomini; T F Blaschke
Journal:  Life Sci       Date:  1980-09-01       Impact factor: 5.037

4.  Effective routes of drug administration during cardiac arrest.

Authors:  J S Redding; J S Asuncion; J W Pearson
Journal:  Anesth Analg       Date:  1967 Mar-Apr       Impact factor: 5.108

5.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

Authors:  L F Prescott; K K Adjepon-Yamoah; R G Talbot
Journal:  Br Med J       Date:  1976-04-17

6.  Use of atropine in patients with acute myocardial infarction and sinus bradycardia.

Authors:  M M Scheinman; D Thorburn; J A Abbott
Journal:  Circulation       Date:  1975-10       Impact factor: 29.690

Review 7.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  Effects of dobutamine in patients with acute myocardial infarction.

Authors:  T A Gillespie; H D Ambos; B E Sobel; R Roberts
Journal:  Am J Cardiol       Date:  1977-04       Impact factor: 2.778

9.  Endotracheal administration of atropine sulfate.

Authors:  M I Greenberg; D V Mayeda; R Chrzanowski; D Brumwell; S I Baskin; J R Roberts
Journal:  Ann Emerg Med       Date:  1982-10       Impact factor: 5.721

10.  Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man.

Authors:  W E Clutter; D M Bier; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

View more
  9 in total

Review 1.  The place of intracardiac injections in the treatment of cardiac arrest.

Authors:  A Pedersen; H Jespersen; C Torp-Pedersen
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest.

Authors:  L P Huyghens; W A Buylaert; L Corne; M T Rosseel; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Pharmacokinetics and pharmacodynamics in critically ill patients.

Authors:  H J Mann; D W Fuhs; F B Cerra
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 5.  Myocardial uptake of drugs and clinical effects.

Authors:  J D Horowitz; A C Powell
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 6.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

7.  Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.

Authors:  Yeamin Huh; Richard F Keep; David E Smith
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

Review 8.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.

Authors:  W A Buylaert; L L Herregods; E P Mortier; M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

Review 9.  Clinical pharmacological and therapeutic considerations in general intensive care. A review.

Authors:  M L Farina; M Bonati; G Iapichino; A Pesenti; F Procaccio; L Boselli; M Langer; A Graziina; G Tognoni
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.